Related references
Note: Only part of the references are listed.Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the
Bart Koopman et al.
CLINICAL LUNG CANCER (2022)
Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy
Fan Chen et al.
ADVANCED SCIENCE (2021)
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
Yue Pan et al.
FRONTIERS IN ONCOLOGY (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J. Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Giuseppe Lamberti et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives
Florian Guisier et al.
CLINICAL LUNG CANCER (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
ALK inhibitors, resistance development, clinical trials
J. M. Rothenstein et al.
CURRENT ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer
Dong Ha Kim et al.
TARGETED ONCOLOGY (2018)
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Sean Khozin et al.
CLINICAL CANCER RESEARCH (2017)
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
Jin Kyung Rho et al.
CANCER RESEARCH (2017)
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Keiichiro Suzuki et al.
NATURE (2016)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein et al.
CANCER RESEARCH (2015)
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini et al.
EMBO REPORTS (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Hideko Isozaki et al.
CANCERS (2015)
Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases
Young Hoon Sung et al.
GENOME RESEARCH (2014)
Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
Bin Shen et al.
NATURE METHODS (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Annette O. Walter et al.
CANCER DISCOVERY (2013)
A view on EGFR-targeted therapies from the oncogene-addiction perspective
Rolando Perez et al.
FRONTIERS IN PHARMACOLOGY (2013)
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Jean-Charles Soria et al.
CANCER TREATMENT REVIEWS (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Linda Madisen et al.
NATURE NEUROSCIENCE (2010)
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
Jin Kyung Rho et al.
LUNG CANCER (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji et al.
CANCER CELL (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
